世界の非侵襲的癌診断市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Non-Invasive Cancer Diagnostics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4172 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、非侵襲的癌診断のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（CTC、CTNAS、エクソソーム）、用途別市場規模（血、尿、唾液）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・非侵襲的癌診断の市場動向 ・企業の競争状況、市場シェア ・非侵襲的癌診断の種類別市場規模（CTC、CTNAS、エクソソーム） ・非侵襲的癌診断の用途別市場規模（血、尿、唾液） ・非侵襲的癌診断の北米市場規模2016-2027（アメリカ、カナダ） ・非侵襲的癌診断のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・非侵襲的癌診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非侵襲的癌診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・非侵襲的癌診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Gen-Probe Inc、Digene Corporation、Quest Diagnostics Inc、Cancer, Genetics Inc、BIOVIEW Inc、AVIVA Biosciences Corporation、Laboratory Corporation of America Holdings (LabCorp)、A&G Pharmaceutical、Affymetrix Inc、Precision Therapeutics） ・結論

Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.

The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization’s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.

Market Analysis and Insights: Global Non-Invasive Cancer Diagnostics Market
The global Non-Invasive Cancer Diagnostics market size is projected to reach US$ 140850 million by 2026, from US$ 107340 million in 2019, at a CAGR of 3.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-Invasive Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-Invasive Cancer Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-Invasive Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-Invasive Cancer Diagnostics market.

Global Non-Invasive Cancer Diagnostics Scope and Market Size
Non-Invasive Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Invasive Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
CTCs
CTNAS
Exosomes

Segment by Application
Blood
Urine
Saliva

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Invasive Cancer Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 CTCs
1.2.3 CTNAS
1.2.4 Exosomes
1.3 Market by Application
1.3.1 Global Non-Invasive Cancer Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Blood
1.3.3 Urine
1.3.4 Saliva
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Non-Invasive Cancer Diagnostics Market Perspective (2016-2027)
2.2 Non-Invasive Cancer Diagnostics Growth Trends by Regions
2.2.1 Non-Invasive Cancer Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Invasive Cancer Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Non-Invasive Cancer Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Non-Invasive Cancer Diagnostics Industry Dynamic
2.3.1 Non-Invasive Cancer Diagnostics Market Trends
2.3.2 Non-Invasive Cancer Diagnostics Market Drivers
2.3.3 Non-Invasive Cancer Diagnostics Market Challenges
2.3.4 Non-Invasive Cancer Diagnostics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Non-Invasive Cancer Diagnostics Players by Revenue
3.1.1 Global Top Non-Invasive Cancer Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Non-Invasive Cancer Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Non-Invasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Invasive Cancer Diagnostics Revenue
3.4 Global Non-Invasive Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Non-Invasive Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Invasive Cancer Diagnostics Revenue in 2020
3.5 Non-Invasive Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Non-Invasive Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Non-Invasive Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Invasive Cancer Diagnostics Breakdown Data by Type
4.1 Global Non-Invasive Cancer Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Type (2022-2027)

5 Non-Invasive Cancer Diagnostics Breakdown Data by Application
5.1 Global Non-Invasive Cancer Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Non-Invasive Cancer Diagnostics Market Size (2016-2027)
6.2 North America Non-Invasive Cancer Diagnostics Market Size by Type
6.2.1 North America Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Non-Invasive Cancer Diagnostics Market Size by Type (2016-2027)
6.3 North America Non-Invasive Cancer Diagnostics Market Size by Application
6.3.1 North America Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Non-Invasive Cancer Diagnostics Market Size by Application (2016-2027)
6.4 North America Non-Invasive Cancer Diagnostics Market Size by Country
6.4.1 North America Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Non-Invasive Cancer Diagnostics Market Size (2016-2027)
7.2 Europe Non-Invasive Cancer Diagnostics Market Size by Type
7.2.1 Europe Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Non-Invasive Cancer Diagnostics Market Size by Type (2016-2027)
7.3 Europe Non-Invasive Cancer Diagnostics Market Size by Application
7.3.1 Europe Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Non-Invasive Cancer Diagnostics Market Size by Application (2016-2027)
7.4 Europe Non-Invasive Cancer Diagnostics Market Size by Country
7.4.1 Europe Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Type
8.2.1 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Application
8.3.1 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region
8.4.1 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Non-Invasive Cancer Diagnostics Market Size (2016-2027)
9.2 Latin America Non-Invasive Cancer Diagnostics Market Size by Type
9.2.1 Latin America Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Non-Invasive Cancer Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Non-Invasive Cancer Diagnostics Market Size by Application
9.3.1 Latin America Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Non-Invasive Cancer Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Non-Invasive Cancer Diagnostics Market Size by Country
9.4.1 Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Type
10.2.1 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Application
10.3.1 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country
10.4.1 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Gen-Probe Inc
11.1.1 Gen-Probe Inc Company Details
11.1.2 Gen-Probe Inc Business Overview
11.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Introduction
11.1.4 Gen-Probe Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.1.5 Gen-Probe Inc Recent Development
11.2 Digene Corporation
11.2.1 Digene Corporation Company Details
11.2.2 Digene Corporation Business Overview
11.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Introduction
11.2.4 Digene Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.2.5 Digene Corporation Recent Development
11.3 Quest Diagnostics Inc
11.3.1 Quest Diagnostics Inc Company Details
11.3.2 Quest Diagnostics Inc Business Overview
11.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Introduction
11.3.4 Quest Diagnostics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.3.5 Quest Diagnostics Inc Recent Development
11.4 Cancer, Genetics Inc
11.4.1 Cancer, Genetics Inc Company Details
11.4.2 Cancer, Genetics Inc Business Overview
11.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Introduction
11.4.4 Cancer, Genetics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.4.5 Cancer, Genetics Inc Recent Development
11.5 BIOVIEW Inc
11.5.1 BIOVIEW Inc Company Details
11.5.2 BIOVIEW Inc Business Overview
11.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Introduction
11.5.4 BIOVIEW Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.5.5 BIOVIEW Inc Recent Development
11.6 AVIVA Biosciences Corporation
11.6.1 AVIVA Biosciences Corporation Company Details
11.6.2 AVIVA Biosciences Corporation Business Overview
11.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Introduction
11.6.4 AVIVA Biosciences Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.6.5 AVIVA Biosciences Corporation Recent Development
11.7 Laboratory Corporation of America Holdings (LabCorp)
11.7.1 Laboratory Corporation of America Holdings (LabCorp) Company Details
11.7.2 Laboratory Corporation of America Holdings (LabCorp) Business Overview
11.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Introduction
11.7.4 Laboratory Corporation of America Holdings (LabCorp) Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.7.5 Laboratory Corporation of America Holdings (LabCorp) Recent Development
11.8 A&G Pharmaceutical
11.8.1 A&G Pharmaceutical Company Details
11.8.2 A&G Pharmaceutical Business Overview
11.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Introduction
11.8.4 A&G Pharmaceutical Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.8.5 A&G Pharmaceutical Recent Development
11.9 Affymetrix Inc
11.9.1 Affymetrix Inc Company Details
11.9.2 Affymetrix Inc Business Overview
11.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Introduction
11.9.4 Affymetrix Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.9.5 Affymetrix Inc Recent Development
11.10 Precision Therapeutics
11.10.1 Precision Therapeutics Company Details
11.10.2 Precision Therapeutics Business Overview
11.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Introduction
11.10.4 Precision Therapeutics Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021)
11.10.5 Precision Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non-Invasive Cancer Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of CTCs
Table 3. Key Players of CTNAS
Table 4. Key Players of Exosomes
Table 5. Global Non-Invasive Cancer Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Non-Invasive Cancer Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Non-Invasive Cancer Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Non-Invasive Cancer Diagnostics Market Share by Regions (2016-2021)
Table 9. Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Non-Invasive Cancer Diagnostics Market Share by Regions (2022-2027)
Table 11. Non-Invasive Cancer Diagnostics Market Trends
Table 12. Non-Invasive Cancer Diagnostics Market Drivers
Table 13. Non-Invasive Cancer Diagnostics Market Challenges
Table 14. Non-Invasive Cancer Diagnostics Market Restraints
Table 15. Global Non-Invasive Cancer Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Non-Invasive Cancer Diagnostics Market Share by Players (2016-2021)
Table 17. Global Top Non-Invasive Cancer Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Invasive Cancer Diagnostics as of 2020)
Table 18. Ranking of Global Top Non-Invasive Cancer Diagnostics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Non-Invasive Cancer Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Non-Invasive Cancer Diagnostics Product Solution and Service
Table 22. Date of Enter into Non-Invasive Cancer Diagnostics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type (2016-2021)
Table 26. Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Non-Invasive Cancer Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Application (2016-2021)
Table 30. Global Non-Invasive Cancer Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Gen-Probe Inc Company Details
Table 63. Gen-Probe Inc Business Overview
Table 64. Gen-Probe Inc Non-Invasive Cancer Diagnostics Product
Table 65. Gen-Probe Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 66. Gen-Probe Inc Recent Development
Table 67. Digene Corporation Company Details
Table 68. Digene Corporation Business Overview
Table 69. Digene Corporation Non-Invasive Cancer Diagnostics Product
Table 70. Digene Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 71. Digene Corporation Recent Development
Table 72. Quest Diagnostics Inc Company Details
Table 73. Quest Diagnostics Inc Business Overview
Table 74. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product
Table 75. Quest Diagnostics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 76. Quest Diagnostics Inc Recent Development
Table 77. Cancer, Genetics Inc Company Details
Table 78. Cancer, Genetics Inc Business Overview
Table 79. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product
Table 80. Cancer, Genetics Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 81. Cancer, Genetics Inc Recent Development
Table 82. BIOVIEW Inc Company Details
Table 83. BIOVIEW Inc Business Overview
Table 84. BIOVIEW Inc Non-Invasive Cancer Diagnostics Product
Table 85. BIOVIEW Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 86. BIOVIEW Inc Recent Development
Table 87. AVIVA Biosciences Corporation Company Details
Table 88. AVIVA Biosciences Corporation Business Overview
Table 89. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product
Table 90. AVIVA Biosciences Corporation Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 91. AVIVA Biosciences Corporation Recent Development
Table 92. Laboratory Corporation of America Holdings (LabCorp) Company Details
Table 93. Laboratory Corporation of America Holdings (LabCorp) Business Overview
Table 94. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product
Table 95. Laboratory Corporation of America Holdings (LabCorp) Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 96. Laboratory Corporation of America Holdings (LabCorp) Recent Development
Table 97. A&G Pharmaceutical Company Details
Table 98. A&G Pharmaceutical Business Overview
Table 99. A&G Pharmaceutical Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 100. A&G Pharmaceutical Recent Development
Table 101. Affymetrix Inc Company Details
Table 102. Affymetrix Inc Business Overview
Table 103. Affymetrix Inc Non-Invasive Cancer Diagnostics Product
Table 104. Affymetrix Inc Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 105. Affymetrix Inc Recent Development
Table 106. Precision Therapeutics Company Details
Table 107. Precision Therapeutics Business Overview
Table 108. Precision Therapeutics Non-Invasive Cancer Diagnostics Product
Table 109. Precision Therapeutics Revenue in Non-Invasive Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 110. Precision Therapeutics Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Invasive Cancer Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. CTCs Features
Figure 3. CTNAS Features
Figure 4. Exosomes Features
Figure 5. Global Non-Invasive Cancer Diagnostics Market Share by Application: 2020 VS 2027
Figure 6. Blood Case Studies
Figure 7. Urine Case Studies
Figure 8. Saliva Case Studies
Figure 9. Non-Invasive Cancer Diagnostics Report Years Considered
Figure 10. Global Non-Invasive Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Non-Invasive Cancer Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Non-Invasive Cancer Diagnostics Market Share by Regions: 2020 VS 2027
Figure 13. Global Non-Invasive Cancer Diagnostics Market Share by Regions (2022-2027)
Figure 14. Global Non-Invasive Cancer Diagnostics Market Share by Players in 2020
Figure 15. Global Top Non-Invasive Cancer Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Invasive Cancer Diagnostics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Non-Invasive Cancer Diagnostics Revenue in 2020
Figure 17. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type (2016-2021)
Figure 18. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type (2022-2027)
Figure 19. North America Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Non-Invasive Cancer Diagnostics Market Share by Type (2016-2027)
Figure 21. North America Non-Invasive Cancer Diagnostics Market Share by Application (2016-2027)
Figure 22. North America Non-Invasive Cancer Diagnostics Market Share by Country (2016-2027)
Figure 23. United States Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Non-Invasive Cancer Diagnostics Market Share by Type (2016-2027)
Figure 27. Europe Non-Invasive Cancer Diagnostics Market Share by Application (2016-2027)
Figure 28. Europe Non-Invasive Cancer Diagnostics Market Share by Country (2016-2027)
Figure 29. Germany Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Non-Invasive Cancer Diagnostics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Non-Invasive Cancer Diagnostics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Non-Invasive Cancer Diagnostics Market Share by Region (2016-2027)
Figure 39. China Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Non-Invasive Cancer Diagnostics Market Share by Type (2016-2027)
Figure 47. Latin America Non-Invasive Cancer Diagnostics Market Share by Application (2016-2027)
Figure 48. Latin America Non-Invasive Cancer Diagnostics Market Share by Country (2016-2027)
Figure 49. Mexico Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Non-Invasive Cancer Diagnostics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Non-Invasive Cancer Diagnostics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Non-Invasive Cancer Diagnostics Market Share by Country (2016-2027)
Figure 55. Turkey Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Non-Invasive Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Gen-Probe Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 59. Digene Corporation Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 60. Quest Diagnostics Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 61. Cancer, Genetics Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 62. BIOVIEW Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 63. AVIVA Biosciences Corporation Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 64. Laboratory Corporation of America Holdings (LabCorp) Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 65. A&G Pharmaceutical Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 66. Affymetrix Inc Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 67. Precision Therapeutics Revenue Growth Rate in Non-Invasive Cancer Diagnostics Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---